SII pauses India trial of COVID-19 vaccine: Move may delay release but inspires confidence in process, say experts

It is standard procedure to pause trial until further information is obtained about any unexplained symptom or any developments in a recipient's health

FP Staff September 10, 2020 22:25:12 IST
SII pauses India trial of COVID-19 vaccine: Move may delay release but inspires confidence in process, say experts

Representational image.

Clinical trials for AstraZeneca’s coronavirus vaccine candidate have been paused in India, said Serum Institute of India on Thursday, days after similar trials were halted in the UK after a recipient developed a “potentially unexplained” illness.

The move also comes after the company received a notice from the Drugs Controller General of India (DCGI) for not submitting casualty analysis of the "reported serious adverse events".

Why was the vaccine trial paused?

It all started when one of the vaccine recipients developed an unspecified serious illness in the UK. It is not yet clear whether the vaccine and the onset of disease are co-related. But it is standard procedure to pause trial until further information is obtained about any unexplained symptom or developments in a recipient.

AstraZeneca, a Bretish-Swedish drug company, which is manufacturing the vaccine in a tie-up with Oxford University, didn't reveal any information about the possible side effect except to call it "a potentially unexplained illness".

The health news site STAT first reported the pause in testing, saying the possible side effect occurred in the UK.

It’s likely that the unexplained illness was serious enough to require hospitalisation and not a mild side effect such as fever or muscle pain, said Deborah Fuller, a University of Washington researcher who is working on a different COVID-19 vaccine that has not yet started human testing.

Earlier-stage studies of the Oxford vaccine canddiate hadn't revealed any serious side effects, but that's a key reason for doing ever-larger phases of research — to widen the search for any reactions.

Meanwhile, it is important to note that temporary holds of large medical studies aren't unusual, and investigating any serious or unexpected reaction is a mandatory part of safety testing. AstraZeneca pointed out that it's possible the problem could be a coincidence; illnesses of all sorts could arise in studies of thousands of people.

How does it impact search for coronavirus vaccine?

Even though such interruptions in last-stage trials of drugs and vaccines are not uncommon, the suspension of trials, while temporary, may offset hopes of an early vaccine.

Scientists have been scrambling to develop a vaccine against the coronavirus since the outbreak began, and experts across various countries are testing several vaccine candidates. Due to the severity of the situation, the world has even witnessed calls to fast-track trials to ensure an early launch of vaccine. On average, vaccine development can take 10-15 years.

The pause on the last-stage trials may offset the release date that SII and AstraZeneca were hoping for.

“We are working to expedite the review of the single event to minimise any potential impact on the trial timeline,” AstraZeneca statement said.

SII, which was responsible for carrying out the trials in India, however, refused to comment on how the pause will effect the production timeline.

"We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials. We are following DCGI’s instructions and will not be able to comment further on trials. You can connect with DCGI for more updates on this front," SII said.

Experts call pharma giant's move to pause trial despite public glare 'reassuring'

However, apart from a possible delay in production of vaccine, public health experts feel the decision to pause trials was actually encouraging.

“This is not something to be alarmed about,” Fuller said. Instead, it’s reassuring that the company is pausing the study to figure out what’s happening and carefully monitoring the health of study participants.

Dr Francis Collins, director of US National Institutes of Health said, "This ought to be reassuring... When we say we are going to focus first on safety and make no compromises, here is Exhibit A of how that is happening in practice."

Angela Rasmussen, a virologist at Columbia University in New York, tweeted that the illness may be unrelated to the vaccine, "but the important part is that this is why we do trials before rolling out a vaccine to the general public".

Rasmussen's comments bring to light the importance of sticking to the due diligence in vaccine and drug trials.

During the third and final stage of testing, researchers look for any signs of possible side effects that may have gone undetected in earlier patient research. Because of their large size, these studies are considered the most important phase for picking up less common side effects and establishing safety.

The trials also assess effectiveness by tracking who gets sick and who doesn’t between patients getting the vaccine and those receiving a dummy shot.

This process isn't new — phase 3 studies of vaccines and therapies are always done this way — though they are rarely in the spotlight.

This especially becomes important in the backdrop of reports that countries were trying to fast-track their vaccine trials for political reasons.

This week news broke that the US Centers for Disease Control and Prevention asked states to sweep away red tape that could prevent a network of vaccine distribution centres being "fully operational by 1 November, 2020". The country faces its presidential elections this year on 3 November.

The US Food and Drug Administration has also raised the possibility that a vaccine might be given emergency authorisation before the end of trials.

President Donald Trump dangled the possibility in front of supporters last week at the Republican National Convention saying the US "will produce a vaccine before the end of the year, or maybe even sooner".

Furthermore, Russia had launched its vaccine Sputnik V last month without conducting phase 3 trials. Reports said that human trials of the Sputnik V vaccine only began in June, at the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow, and fewer than 200 people were tested in phases 1 and 2.

The vaccine was  released for public distribution on 7 September 2020 to the country's population.

Brian Oliver, who leads the Respiratory Molecular Pathogenesis Group at UTS had told ABC News at the time of Sputnik V's announcement, "In some ways, the approach reported to be taken in Russia is to have a phase 3 trial on the whole population. However, if the vaccination proves to be successful, I'm sure that people will ask why other countries didn't also take this approach."

The roadblock in the AstraZeneca’s coronavirus vaccine trial should reinstate the importance of a larger study before a possible vaccine is released to the world population.

With inputs from agencies

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Vaccine messaging faces unprecedented test with COVID-19 – success of a vaccine hinges on it
World

Vaccine messaging faces unprecedented test with COVID-19 – success of a vaccine hinges on it

In the past, vaccine messaging has drawn on anti-polarization strategies to try building consensus around contentious issues.

Bharat Biotech to begin Phase-3 humans trials of COVAXIN candidate from 15 Oct in Punjab
India

Bharat Biotech to begin Phase-3 humans trials of COVAXIN candidate from 15 Oct in Punjab

Punjab CM Amarinder Singh gave stern directives about the poor not being pulled into trials without consent and understanding of the potential dangers.

India's COVID-19 tally surpasses 50 lakh with 90,123 new cases: AstraZeneca trials to resume
India

India's COVID-19 tally surpasses 50 lakh with 90,123 new cases: AstraZeneca trials to resume

The Serum Institute of India, which had paused phase 2 and phase 3 trials of the Oxford University's vaccine, received the go-ahead from the DCGI to resume the trials in India